Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://covid19.nih.gov/

About this Publication
Title
The National Lung Screening Trial Premise of Null and Chest Radiography Equivalence Is Open to Question.
Pubmed ID
26204275 (View this publication on the PubMed website)
Publication
AJR Am J Roentgenol. 2015 Aug; Volume 205 (Issue 2): Pages 278-9
Authors

Reich JM, Kim JS

Abstract

OBJECTIVE: Lung cancer screening guidelines are based on the National Lung Screening Trial (NLST) that used chest radiographic control subjects on the premise of the reported mortality equivalence in chest radiography versus unscreened persons in the NLST-eligible subgroup of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. The purpose of this article is to discuss concerns regarding the validity of the NLST premise of chest radiography and null screening equivalence.

CONCLUSION: Anomalous findings combined with the failure of CT trials using unscreened control subjects to replicate the benefits of the NLST open to question the validity of this premise.

Related CDAS Studies